Current research status and future directions of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

Core Tip

Core Tip: Hepatic arterial infusion chemotherapy (HAIC) has been shown to offer significantly superior efficacy and safety compared to traditional treatments such as Sorafenib and transarterial chemoembolization for patients suffering from advanced hepatocellular carcinoma. By directly delivering high concentrations of chemotherapeutic agents to the liver tumor through the hepatic artery, HAIC maximizes tumoricidal effects while minimizing systemic side effects. This article underscores the promising clinical outcomes associated with HAIC. Through continued investigation and validation, HAIC has the potential to become a cornerstone in the treatment paradigm for advanced hepatocellular carcinoma, providing patients with a more effective and safer therapeutic option.